Abstract: Noninvasive imaging plays an important role in determining the size of the transcatheter heart valve (THV) in preparation of a transcatheter aortic valve replacement (TAVR) procedure. The identification of the coronary cuspid landmarks or nadirs of each cusp plays a key role in determining the reference points for the two-dimensional (2D) images of the THV. Rather than using nadirs that are currently identified manually upon inspection of 2D computed tomography (CT) images, the methods and systems of the present disclosure utilizing structured 3D dataset of cusps to simultaneously determine the nadirs, which are especially beneficial, particularly when the sizes of cusps have significant difference (i.e., Type 1 aortic valve with two fused leaflets) or the aortic root has a bicuspid configuration rather than a tricuspid configuration.

Abstract: An inspection system for capturing a topography of a surface includes a support frame configured to be positioned over the surface, at least three light sources configured to be mounted at different locations on the support frame, and at least two cameras each having a viewing direction and configured to be mounted at different locations on the support frame in a manner such that the viewing direction of each camera points generally toward a common region of the surface. The inspection system also includes a processor configured to: temporarily activate the light sources one at a time and cause all the cameras to capture a respective plurality of images of the common region each time a light source is activated, and combine the images in a manner that results in a reconstructed surface representing the topography of the common region.

Abstract: Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue. In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspension of one or more ingredients. In embodiments of the present invention, amounts of the formulation and/or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms.

Abstract: Systems, methods, and apparatus for satellite operations with secure enclave for secure inband hosted payload operations are disclosed. In one or more embodiments, a method for payload operations comprises receiving, by a vehicle, host commands from a satellite operation portion of a host spacecraft operations center (SOC). The method further comprises reconfiguring a payload and at least bus component on the vehicle according to the host commands. Also, the method comprises transmitting, by the vehicle, host telemetry to the satellite operation portion of the host SOC. In addition, the method comprises receiving, by the vehicle, hosted commands from a secure enclave of the host SOC. Additionally, the method comprises reconfiguring the payload on the vehicle according to the hosted commands. Further, the method comprises transmitting, by a payload antenna on the vehicle, host payload data, hosted payload data, and the encrypted hosted telemetry to the secure enclave.

Abstract: The present disclosure provides compositions and methods for the targeted modification of RNA molecules by RNA prime editing. The compositions and methods may be conducted invitro or in vivo within cells (e.g., human cells) for the therapeutic correction of disease-causing mutations and/or installation of motifs or mutations in RNA molecules of interest as a tool for scientific research. The disclosure provides compositions and methods for conducting RNA prime editing of a target RNA molecule (e.g., an RNA transcript) that enables the incorporation of one or more nucleotide changes and/or targeted mutagenesis of a target RNA molecule. The nucleotide change can include a single-nucleotide change, an insertion of one or more nucleotides, or a deletion of one or more nucleotides.

Abstract: Provided herein are pharmaceutical compositions (e.g., oral dosage formulations) comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, and a carrier or diluent. Also provided herein are methods of preparing and methods of using the pharmaceutical compositions.

Abstract: The present application describes a method including one or more steps. One step of the method includes receiving, at a gateway including an encrypted pathway, traffic from a third party originating outside a multi-hop network intended for a client inside the network. Another step of the method includes determining, using a trained machine learning model, a probe of the received traffic attempting to obtain confidential information about the multi-hop network. Yet another step of the method includes flagging the third party based on determined probe.

Abstract: Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue. In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspension of one or more ingredients. In embodiments of the present invention, amounts of the formulation and/or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms.

Abstract: Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue. In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspensions of one or more ingredients. In embodiments of the present invention, amounts of the formulation and/or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms.

Abstract: Provided herein are pharmaceutical compositions (e.g., oral dosage formulations) comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, and a carrier or diluent. Also provided herein are methods of preparing and methods of using the pharmaceutical compositions.

Abstract: Provided herein a circuit protection devices including a fusible element attached to a ceramic substrate, the fusible element comprising a paste including a plurality of nickel particles.

Abstract: Systems, methods, and apparatus for satellite operations with a secure enclave for secure hosted payload operations are disclosed. In one or more embodiments, a disclosed method for payload operations comprises receiving, by a command receiver on a vehicle (e.g., a satellite), host commands from a host spacecraft operations center (SOC). The method further comprises reconfiguring a host payload on the vehicle according to the host commands. Also the method comprises transmitting, by a telemetry transmitter on the vehicle, host payload telemetry to the host SOC. In addition, the method comprises receiving, by a payload antenna on the vehicle, hosted commands from a secure enclave of the host SOC. Additionally, the method comprises reconfiguring a hosted payload on the vehicle according to the hosted commands. Further, the method comprises transmitting, by the payload antenna, host payload data, hosted payload data, and hosted telemetry to the secure enclave of the host SOC.

Abstract: Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue. In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspensions of one or more ingredients. In embodiments of the present invention, amounts of the formulation and/or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms.

Abstract: Described herein are methods and computer systems for classification of CD8 T-cell topology using a patient response-based linear cutoff model. A plurality of histology images of tissue samples in a plurality of patients are received by a computer system. An image analysis of the plurality of histology images is performed to obtain a CD8+ T-cell abundance in the tumor parenchyma and stroma in each of the plurality of histology images. Real inflammation scores and tumor infiltration scores are determined based on a polar coordinate transformation of the CD8+ T-cell abundance in the tumor parenchyma and stroma. Based on the real inflammation scores and tumor infiltration scores, a feature space is generated, and linear boundaries or linear cutoffs between a plurality of classifications in the feature space are identified based on the real inflammation scores, the tumor infiltration scores, and patient response data.

Abstract: A testing method accesses tracing data comprising a plurality of tracing records corresponding to a plurality of test cases executed on a target system. The target system includes a plurality of microservices configured in accordance with a REST API. A dynamic test analyzer accesses the tracing data and imports a definition of the REST API. The analyzer checks each tracing record for consistency with the API definition. Based on this checking of the tracing records, one or more coverage metrics may be calculated. If any one or more of the one or more coverage metrics fails to exceed a threshold coverage, a testing action may be required. In some cases, the testing action may be selected from either seeking additional coverage of the APIs included in the target system or seeking additional test result coverage.

Abstract: A polishing system includes a pressure system, a substrate carrier including a membrane, a first sensor, and a control system. A first compartment of the membrane is fluidly coupled to the pressure system. The first sensor is configured to monitor the pressure system and produce a first output based on conditions detected in the pressure system. The control system coupled to the first sensor and configured to process the first output to produce a first processed output, and the control system configured to compare the first processed output to a threshold to detect a presence of a fluid in the pressure system.

Abstract: A cleaning process monitoring system, comprising: a cleaning container comprising an inlet for receiving a cleaning solution and an outlet for draining a waste solution; a particle detector coupled to the outlet and configured to measure a plurality of particle parameters associated with the waste solution so as to provide a real-time monitoring of the cleaning process; a pump coupled to the cleaning container and configured to provide suction force to draw solution through the cleaning system; a controller coupled to the pump and the particle detector and configured to receive the plurality of particle parameters from the particle detector and to provide control to the cleaning system; and a host computer coupled to the controller and configured to provide at least one control parameter to the controller.

Abstract: Provided herein are pharmaceutical compositions (e.g., oral dosage formulations) comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, and a carrier or diluent. Also provided herein are methods of preparing and methods of using the pharmaceutical compositions.

Abstract: A method of processing a substrate according to a PECVD process is described. Temperature profile of the substrate is adjusted to change deposition rate profile across the substrate. Plasma density profile is adjusted to change deposition rate profile across the substrate. Chamber surfaces exposed to the plasma are heated to improve plasma density uniformity and reduce formation of low quality deposits on chamber surfaces. In situ metrology may be used to monitor progress of a deposition process and trigger control actions involving substrate temperature profile, plasma density profile, pressure, temperature, and flow of reactants.

Abstract: An inexpensive test device compares and contrasts a plurality of pigmented tests for a biomarker, organism or other substance for a relative presence of each. Each biomarker is present in a urine sample, and the pigmented test renders a color shade indicative of a respective proportion or quantity. Collection of the pigmented test results in a series of transparent vials allowing a common line of sight through each vial to result in an appearance of a blended or combined color, similar to viewing color filters in line. A predetermined control group of color combinations provides a comparison for respective concentrations of each biomarker present in the sample. In one approach, a first pigmented test results in an orange-yellow shade and a second pigmented test results in a blue shade that, when viewed inline, appear as a green, brown or purple shade indicative of relative percentages denoted by each respective test.